Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLorenzo FalchiJBJoshua BrodyDMDaniel Morillo

Discussion

Loading...

Member takes

Overview

Efficacy and safety of epcoritamab + R-CHOP reveals 80% progression-free survival in patients with IPI scores 3-5.

Key Points

  • Overall response rate reached 98% with a complete response rate of 85% after treatment.
  • Median follow-up of 38.8 months showed sustained remissions, with 80% of patients progression-free at 33 months.
  • Patients received epcoritamab plus R-CHOP as a fixed-duration treatment in the EPCORE NHL-2 trial, demonstrating high efficacy.
  • Long-term results may support epcoritamab + R-CHOP as a standard option for high-risk DLBCL, highlighting safety and efficacy.

Cite This Study

Falchi et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5adhttps://doi.org/10.1182/blood-2025-1955
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma2025
  2. 2Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response2025
  3. 3Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-32025 · 2 citations
  4. 4Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 1 citations
  5. 5Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial2025